Minze Health secures $5.3m funding to expand urology digital health solutions in the US, Germany, and France

Minze Health, a leader in digital health solutions for urology, has secured a substantial $5.3 million in a funding round led by existing investors, including White Fund, Capricorn Digital Growth Fund, and the Flemish investment company PMV. New investor imec.istart future fund also participated, marking a pivotal step forward in Minze Health’s international expansion strategy.

Pioneering Digital Therapeutics for Urology

The company intends to use the capital to develop and launch Prescription Digital Therapeutics (PDTs) targeting patients with urinary dysfunctions, focusing initially on the German and French markets. Additionally, Minze Health plans to leverage the investment to expand its innovative at-home diagnostic solutions to the United States, a significant move aimed at transforming the urology landscape.

Global Reach and Impact

Minze Health’s solutions have already impacted over 160,000 patients worldwide, earning the trust of clinicians in over 20 countries. The company offers a suite of digital diagnostics, remote patient monitoring, and digital therapeutic products, establishing itself as a leading player in the digital health urology market.

Expanding the US Market with Homeflow

A significant portion of the funding will be directed towards expanding Minze Health’s Homeflow and Diary Pod products in the US market. Homeflow, an at-home uroflowmetry system, benefits from recently introduced Category III CPT billing codes. These codes open up opportunities to support patients with benign prostatic hyperplasia (BPH), a condition affecting over 14 million men in the United States. The home-based monitoring technology provides continuous data, allowing clinicians to create personalized treatment plans, minimizing the need for frequent clinical visits, and enabling early interventions.

Appointment of Drew Moore: A Strategic Move

To support its ambitious US expansion, Minze Health has appointed Drew Moore as Vice President of Marketing & Sales. With over 20 years of experience in bringing innovative digital healthcare products to market, particularly in the urology sector, Moore’s expertise is expected to be crucial for Minze Health’s growth. His leadership will play a pivotal role in establishing the US office and building a robust team to strengthen Minze Health’s presence.

Prescription Digital Therapeutics: A Growing Market

Beyond the US, Minze Health is set to bring PDTs, app-based treatments, to patients in Germany and France, utilizing the DIGA and PECAN reimbursement schemes. The PDT market is rapidly expanding, driven by the demand for personalized and non-invasive treatment solutions. For urological conditions like lower urinary tract symptoms (LUTS) and overactive bladder (OAB), PDTs provide a holistic approach by addressing physiological, lifestyle, and behavioral aspects through cognitive interventions. These digital therapies empower patients to manage their symptoms remotely, improving patient outcomes while reducing healthcare costs.

Support from Investors

Philippe Stas from White Fund expressed confidence in Minze Health’s vision, stating that their innovative solutions, particularly Homeflow, fill critical gaps in patient care, holding the potential to enhance outcomes for millions globally. Similarly, Ruth Janssens of imec.istart future fund highlighted Minze Health’s progress since its participation in the Imec.Istart program, showing enthusiasm for supporting the company’s US expansion. She noted that Minze’s commitment to addressing unmet needs in urology aligns with their investment philosophy.

CEO Wilfried Woesthuis’s Vision

Minze Health’s CEO, Wilfried Woesthuis, expressed gratitude for the support from both existing and new investors. He emphasized that the funding will help the company expand internationally, bringing innovative products to the urology market. Woesthuis reaffirmed Minze Health’s mission to enhance the quality of life for millions with LUTS conditions such as BPH and OAB.